IGURATIMOD

IGURATIMOD: IGURATIMOD, also known by its brand name T-614, is an oral disease-modifying anti-rheumatic drug (DMARD) used in the treatment of rheumatoid arthritis. It is primarily used in adults with active rheumatoid arthritis who have not responded well to other DMARDs or nonsteroidal anti-inflammatory drugs (NSAIDs).

The mechanism of action of iguratimod is not fully understood, but it is believed to have immunomodulatory and anti-inflammatory effects. It works by inhibiting the production of various inflammatory mediators and cytokines involved in the pathogenesis of rheumatoid arthritis, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and IL-6. Additionally, it has been shown to inhibit the proliferation and activation of certain immune cells, such as T cells and B cells.

The typical dose of iguratimod is 25 mg, taken orally, twice daily. However, the dosing may vary depending on the individual response and the recommendation of the prescribing physician. It is usually administered over an extended period, as the therapeutic effects may take several weeks to manifest.

Common side effects of iguratimod include gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain. Other side effects may include anorexia, elevated liver enzymes, skin rashes, and headaches. It is important to monitor liver function periodically, as iguratimod can cause liver enzyme elevation in some individuals. Precautions should also be taken in patients with a history of liver disease or who are taking other medications that may affect liver function.

Additionally, studies have reported that some patients may experience reversible decreases in white blood cell and platelet counts while taking iguratimod. Regular monitoring of blood counts is advisable during treatment.

As with any medication, it is important to consult a healthcare professional for more personalized information and to discuss potential risks and benefits before starting treatment with iguratimod.